Verona Pharma Secures Debt Financing of as much as $150 Million from Oxford Finance
Verona Pharma plc Non-dilutive capital funds deliberate launch of ensifentrine for COPD LONDON and RALEIGH, N.C., Oct. 17, 2022 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Firm”), declares it has entered right into a debt financing facility (“debt facility”) offering the Firm with entry to as much as $150 million […]
Continue Reading